1. Home
  2. TNXP vs PKOH Comparison

TNXP vs PKOH Comparison

Compare TNXP & PKOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • PKOH
  • Stock Information
  • Founded
  • TNXP 2007
  • PKOH 1907
  • Country
  • TNXP United States
  • PKOH United States
  • Employees
  • TNXP N/A
  • PKOH N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • PKOH Industrial Specialties
  • Sector
  • TNXP Health Care
  • PKOH Industrials
  • Exchange
  • TNXP Nasdaq
  • PKOH Nasdaq
  • Market Cap
  • TNXP 272.0M
  • PKOH 282.2M
  • IPO Year
  • TNXP N/A
  • PKOH N/A
  • Fundamental
  • Price
  • TNXP $49.73
  • PKOH $17.49
  • Analyst Decision
  • TNXP Strong Buy
  • PKOH
  • Analyst Count
  • TNXP 2
  • PKOH 0
  • Target Price
  • TNXP $585.00
  • PKOH N/A
  • AVG Volume (30 Days)
  • TNXP 1.2M
  • PKOH 37.8K
  • Earning Date
  • TNXP 08-15-2025
  • PKOH 08-06-2025
  • Dividend Yield
  • TNXP N/A
  • PKOH 2.90%
  • EPS Growth
  • TNXP N/A
  • PKOH 144.68
  • EPS
  • TNXP N/A
  • PKOH 2.26
  • Revenue
  • TNXP $10,041,000.00
  • PKOH $1,644,000,000.00
  • Revenue This Year
  • TNXP $22.87
  • PKOH $1.80
  • Revenue Next Year
  • TNXP $711.66
  • PKOH $3.97
  • P/E Ratio
  • TNXP N/A
  • PKOH $7.66
  • Revenue Growth
  • TNXP N/A
  • PKOH N/A
  • 52 Week Low
  • TNXP $6.76
  • PKOH $16.26
  • 52 Week High
  • TNXP $130.00
  • PKOH $34.50
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 70.46
  • PKOH 47.06
  • Support Level
  • TNXP $41.64
  • PKOH $16.26
  • Resistance Level
  • TNXP $46.00
  • PKOH $17.95
  • Average True Range (ATR)
  • TNXP 3.70
  • PKOH 0.84
  • MACD
  • TNXP 0.38
  • PKOH -0.03
  • Stochastic Oscillator
  • TNXP 95.84
  • PKOH 44.73

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About PKOH Park-Ohio Holdings Corp.

Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.

Share on Social Networks: